Dr. Reddy's: When Two Blockbusters Exit at Once
Weak stock · India · DR. REDDY S LABORATORIES (DRREDDY.NS) · Analysis as of 2026-09-11
A 69% profit crash, a ₹240 crore quality write-off, and a near 52-week low — Dr. Reddy's Laboratories is navigating its most complex earnings chapter in years. What happens when the two biggest revenue pillars disappear simultaneously, and can the pipeline rescue the story before FY28?
Imagine a sprinter who trained for years, only to stumble at the starting line because both shoes fell off at once. That, in essence, is the earnings narrative gripping Dr. Reddy's Laboratories right now — and the stock at ₹1,143 tells that story with brutal clarity.
---
The Fundamental Fractures
The most jarring data point is the most recent quarter: consolidated net profit plummeted 68.7% year-on-year to just ₹443.5 crore, while revenue contracted 5.5% YoY to ₹8,099.8 crore. Behind this shock lies a double blow that markets had feared but underestimated in its severity.
Headwind #1 — The gRevlimid (lenalidomide) cliff. Dr. Reddy's had enjoyed four years of high-margin, limited-competition sales of generic lenalidomide in the US. That agreement expired in January 2026, instantly removing one of the company's most profitable revenue streams. Street estimates had largely baked in the loss, but the residual drag on the US business — particularly on overall gross margins — proved deeper than modelled.
Headwind #2 — The semaglutide API setback. The company was widely expected to capitalise on the global GLP-1 wave through its Active Pharmaceutical Ingredient (API) business. Instead, a quality-related batch issue forced a ₹240 crore provision, decimating PSAI segment gross margin from 13.2% in Q1FY26 to just 4.5% in Q1FY27 — an extraordinary 870 basis-point collapse within a single segment in one year.
Together, these two events expose a structural margin problem that has been building. Gross margins have compressed steadily — from 60.4% in Q1FY25 to 56.9% in Q1FY26 to 54.7% in Q2FY26, and further deteriorating in the most recent period. SG&A expenses have risen 13–15% year-on-year across consecutive quarters, outpacing revenue growth.
| Metric | Q1FY25 | Q2FY26 | Q1FY27 | |---|---|---|---| | Gross Margin | 60.4% | 54.7% | Significantly compressed | | EBITDA Margin | ~29% | 26.7% | Materially lower | | Net Profit (₹ Cr) | ~1,410 | 1,437 | 443.5 | | YoY Revenue Growth | +11% | +9.8% | -5.5% |
This is now the second consecutive quarter of EBITDA disappointment against Street expectations, a fact that has triggered meaningful analyst action.
---
What Analysts Are Saying
Goldman Sachs trimmed its price target to ₹1,050 from ₹1,075, explicitly citing margin pressure. Motilal Oswal Financial Services (MOFSL) maintains a Neutral stance with a ₹1,125 target, projecting earnings to decline through FY27 before any meaningful revival from FY28 onward. The next potential catalyst — commercial contributions from biosimilar b-abatacept — is not expected until Q4FY27 at the earliest. The wait is long; the current valuation at 29.3x P/E and a PEG ratio of 1.59 is difficult to justify against a near-term earnings contraction cycle.
---
The Technical Landscape
Price action reflects the fundamental deterioration. At ₹1,143, the stock trades near multi-year lows and has shed approximately 23% from its recent highs — a decline that has broken multiple support levels. The ADR equivalent has flirted with its 52-week low. Momentum indicators remain in negative territory: the price is trading below key short-term and medium-term moving averages, with no meaningful base-building visible yet. Volume on down-days has been elevated, a classic sign of institutional distribution. The risk-reward from a purely technical standpoint appears asymmetric against the holder — the next meaningful support zone lies near ₹1,050–₹1,075, coinciding with Goldman Sachs's revised price target.
---
The Road Ahead
Dr. Reddy's is not a structurally broken business. Its branded markets in Russia, India, and Europe continue to grow, and the CDMO business offers a credible long-term runway. However, the near-term earnings trajectory is clearly under pressure, and the pipeline of value-unlocking events (b-abatacept, semaglutide API resolution) is back-end weighted toward FY28. Until gross margins stabilise and the US business demonstrates a consistent quarterly run-rate without one-off headwinds, the market is unlikely to re-rate the stock higher.
The key takeaway: Dr. Reddy's current weakness is not noise — it is a fundamental reset. Investors should watch gross margin trends and US base business quarterly run-rates as the two most critical leading indicators of when the story may turn.
---
Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.